CARBACHOL - Food and Drug Administration

Set ID: 76dbb916-cd7f-7147-fbde-e858c08e0e3c
Type: Indexing - Product Concept
Effective date: 2014-05-08
Version: 1
Source: DailyMed source

Mapped DailyMed Labels#

Label, Relation, Manufacturer table
Label	Relation	Manufacturer	Effective
These highlights do not include all the information needed to use YUVEZZI™ safely and effectively. See full prescribing information for YUVEZZI. YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75% / 0.1%, for topical ophthalmic use Initial U.S. Approval: 2026	Product name	Visus Therapeutics, Inc.	2026-05-27
These highlights do not include all the information needed to use YUVEZZI™ safely and effectively. See full prescribing information for YUVEZZI. YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75% / 0.1%, for topical ophthalmic use Initial U.S. Approval: 2026	Product name	Visus Therapeutics, Inc.	2026-03-19
These highlights do not include all the information needed to use YUVEZZI™ safely and effectively. See full prescribing information for YUVEZZI. YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75% / 0.1%, for topical ophthalmic use Initial U.S. Approval: 2026	Product name	Visus Therapeutics, Inc.	2026-02-19
MIOSTAT™ (CARBACHOL INTRAOCULAR SOLUTION, USP) 0.01%	Product name	Alcon Laboratories, Inc. \| Alcon Research LLC \| Siegfried AG	2023-02-10
Carbastat ®	Product name	Novartis Ophthalmics	2006-09-19

NDC, DailyMed label, Manufacturer table
NDC	DailyMed label	Manufacturer
0065-0023	MIOSTAT™ (CARBACHOL INTRAOCULAR SOLUTION, USP) 0.01%	Alcon Laboratories, Inc. \| Alcon Research LLC \| Siegfried AG
0065-0023-15	MIOSTAT™ (CARBACHOL INTRAOCULAR SOLUTION, USP) 0.01%	Alcon Laboratories, Inc. \| Alcon Research LLC \| Siegfried AG
58768-735	Carbastat ®	Novartis Ophthalmics
58768-735-12	Carbastat ®	Novartis Ophthalmics
84892-275	These highlights do not include all the information needed to use YUVEZZI™ safely and effectively. See full prescribing information for YUVEZZI. YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75% / 0.1%, for topical ophthalmic use Initial U.S. Approval: 2026	Visus Therapeutics, Inc.
84892-275-01	These highlights do not include all the information needed to use YUVEZZI™ safely and effectively. See full prescribing information for YUVEZZI. YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75% / 0.1%, for topical ophthalmic use Initial U.S. Approval: 2026	Visus Therapeutics, Inc.
84892-275-02	These highlights do not include all the information needed to use YUVEZZI™ safely and effectively. See full prescribing information for YUVEZZI. YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75% / 0.1%, for topical ophthalmic use Initial U.S. Approval: 2026	Visus Therapeutics, Inc.
84892-275-30	These highlights do not include all the information needed to use YUVEZZI™ safely and effectively. See full prescribing information for YUVEZZI. YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75% / 0.1%, for topical ophthalmic use Initial U.S. Approval: 2026	Visus Therapeutics, Inc.
84892-275-99	These highlights do not include all the information needed to use YUVEZZI™ safely and effectively. See full prescribing information for YUVEZZI. YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75% / 0.1%, for topical ophthalmic use Initial U.S. Approval: 2026	Visus Therapeutics, Inc.